menu
    • menu
    [{"orgOrder":0,"company":"Pardes Biosciences","sponsor":"FS Development Corp. II","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Merger","leadProduct":"Pomotrelvir","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pardes Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pardes Biosciences \/ FS Development Corp. II","highestDevelopmentStatusID":"8","companyTruncated":"Pardes Biosciences \/ FS Development Corp. II"},{"orgOrder":0,"company":"Pardes Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pomotrelvir","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pardes Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pardes Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pardes Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Pardes Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pomotrelvir","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pardes Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pardes Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pardes Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Pardes Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pomotrelvir","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pardes Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pardes Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pardes Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Pardes Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pomotrelvir","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pardes Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pardes Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pardes Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Pardes Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pomotrelvir","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pardes Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pardes Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pardes Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Pardes Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pomotrelvir","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pardes Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pardes Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pardes Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Pardes Biosciences","sponsor":"MediPacific","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Pomotrelvir","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pardes Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pardes Biosciences \/ MediPacific","highestDevelopmentStatusID":"8","companyTruncated":"Pardes Biosciences \/ MediPacific"},{"orgOrder":0,"company":"Pardes Biosciences","sponsor":"MediPacific","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Pomotrelvir","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pardes Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pardes Biosciences \/ MediPacific","highestDevelopmentStatusID":"8","companyTruncated":"Pardes Biosciences \/ MediPacific"},{"orgOrder":0,"company":"Pardes Biosciences","sponsor":"FS Development Corp. II","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Merger","leadProduct":"Pomotrelvir","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pardes Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pardes Biosciences \/ FS Development Corp. II","highestDevelopmentStatusID":"8","companyTruncated":"Pardes Biosciences \/ FS Development Corp. II"}]

    Find Clinical Drug Pipeline Developments & Deals for Pomotrelvir

    Menu

    Pomotrelvir

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Pardes Biosciences

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Pardes Biosciences

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pomotrelvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : MediPacific

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Pardes Biosciences Announces Closing of Tender Offer

                            Details : Through the acquisition, MediPacific will expand its pipeline with Pardes' COVID-19 antiviral portfolio including, PBI-0451 (pomotrelvir), an investigational coronavirus main protease (Mpro) inhibitor.

                            Product Name : PBI-0451

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            August 31, 2023

                            Lead Product(s) : Pomotrelvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : MediPacific

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Pardes Biosciences

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Pardes Biosciences

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pomotrelvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : MediPacific

                            Deal Size : $125.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Pardes Biosciences Enters into Agreement to be Acquired by MediPacific, Inc. for between $2.02 and $2.19 in Ca...

                            Details : Through the acquisition, MediPacific will expand its pipeline with Pardes' COVID-19 antiviral portfolio including, PBI-0451 (pomotrelvir), an investigational coronavirus main protease (Mpro) inhibitor.

                            Product Name : PBI-0451

                            Product Type : Other Small Molecule

                            Upfront Cash : $125.0 million

                            July 17, 2023

                            Lead Product(s) : Pomotrelvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : MediPacific

                            Deal Size : $125.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Pardes Biosciences

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Pardes Biosciences

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pomotrelvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pardes Biosciences Announces Top-line Results from Phase 2 Trial Evaluating Pomotrelvir for the Treatment of C...

                            Details : PBI-0451 (pomotrelvir) did not meet the primary endpoint measured by the proportion of participants below the limit of detection for infectious SARS-CoV-2 on day 3 of treatment with pomotrelvir versus placebo.

                            Product Name : PBI-0451

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 04, 2023

                            Lead Product(s) : Pomotrelvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Pardes Biosciences

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Pardes Biosciences

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pomotrelvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pardes Biosciences Announces Commencement of Phase 2 Trial Evaluating PBI-0451 for the Treatment of SARS-CoV-2...

                            Details : PBI-0451 is a potential stand-alone, novel, direct-acting oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections in Phase 2 clinical development.

                            Product Name : PBI-0451

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 13, 2022

                            Lead Product(s) : Pomotrelvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Pardes Biosciences

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Pardes Biosciences

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pomotrelvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pardes Biosciences to Present Clinical Data from Ongoing PBI-0451 Phase 1 Trial at Conference On Retroviruses ...

                            Details : PBI-0451 is an investigational orally bioavailable direct-acting antiviral (DAA) inhibitor of the main protease (Mpro), an essential protein required for the replication of coronaviruses, including the novel SARS-CoV-2 that causes COVID-19.

                            Product Name : PBI-0451

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 02, 2022

                            Lead Product(s) : Pomotrelvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Pardes Biosciences

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Pardes Biosciences

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pomotrelvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pardes Biosciences to Present at the International Conference On Antiviral Research 2022

                            Details : PBI-0451, an oral antiviral drug candidate is investigational direct-acting antiviral (DAA) inhibitor of the 3CL protease, is a potential unboosted novel direct-acting for the treatment and prevention of SARS-CoV-2 infections and associated diseases.

                            Product Name : PBI-0451

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 21, 2022

                            Lead Product(s) : Pomotrelvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Pardes Biosciences

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Pardes Biosciences

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pomotrelvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pardes Biosciences Presents Interim Clinical Data from Ongoing PBI-0451 Phase 1 Trial Supporting the Potential...

                            Details : PBI-0451 an orally administered 3CL protease inhibitor of SARS-CoV-2 administered twice-daily as a stand-alone agent achieves and maintains PK exposures anticipated to provide potent antiviral activity against SARS-CoV-2.

                            Product Name : PBI-0451

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 14, 2022

                            Lead Product(s) : Pomotrelvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Pardes Biosciences

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Pardes Biosciences

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pomotrelvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : FS Development Corp. II

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            FSII and Pardes Biosciences Move Towards Merger With the Goal of Tackling COVID-19 via an Oral Antiviral for T...

                            Details : Pardes is currently dosing healthy volunteers in a Phase I clinical study of its protease inhibitor, PBI-0451, that is exploring dosing levels, intervals and regimens. The combined company to play an important role in addressing one of the biggest health...

                            Product Name : PBI-0451

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            December 21, 2021

                            Lead Product(s) : Pomotrelvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : FS Development Corp. II

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Pardes Biosciences

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Pardes Biosciences

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pomotrelvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pardes Biosciences Initiates First-in-Human Trial for PBI-0451, an Oral Antiviral in Development to Treat and ...

                            Details : PBI-0451 works by inhibiting Viral Main Protease (Mpro), a highly conserved key protein in the virus required for its replication, thus blocking the virus’ ability to replicate.

                            Product Name : PBI-0451

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 26, 2021

                            Lead Product(s) : Pomotrelvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Pardes Biosciences

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Pardes Biosciences

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pomotrelvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : FS Development Corp. II

                            Deal Size : $276.0 million

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Pardes Biosciences and FS Development Corp. II Announce Merger Agreement

                            Details : FS Development Corp. II’s trust account and the PIPE financing, and will be used to advance PBI-0451, Pardes’ lead oral antiviral drug candidate to treat and prevent SARS-CoV-2 infections as well as additional candidates from the company’s covalent...

                            Product Name : PBI-0451

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            June 29, 2021

                            Lead Product(s) : Pomotrelvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : FS Development Corp. II

                            Deal Size : $276.0 million

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth